The adjuvant therapy of pemphigus an update

Archives of Dermatology

Volumn 132, Issue 2, 1996, Pages 203-212

  Bystryn, Jean Claude ^a,b   Steinman, Natasha M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE SODIUM SUCCINATE; NICOTINAMIDE; PREDNISOLONE; PREDNISONE; STEROID; TETRACYCLINE; TRIAMCINOLONE ACETONIDE;

ADJUVANT THERAPY; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG MEGADOSE; DRUG THERAPY; HUMAN; INSOMNIA; INTRALESIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PEMPHIGUS; PLASMAPHERESIS; PRIORITY JOURNAL; PUVA; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGUS; PHOTOPHERESIS; PLASMAPHERESIS; PROGNOSIS;

EID: 0030044726     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.2.203     Document Type: Review

References (89)

1. Bystryn J-C Adjuvant therapy of pemphigus. Arch Dermatol. 1984;120:941-951
2. Guillaume J-C, Roujeau J-C, Morel P, et al Controlled study of plasma exchange in pemphigus. Arch Dermatol. 1988;124:1659-1663.
3. Tan-Lim R, Bystryn J-C. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies J Am Acad Dermatol. 1990;22.35-39.
4. Seidenbaum M, David M, Sandbank M The course and prognosis of pemphigus. Int J Dermatol. 1988;120 580-584
5. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris Arch Dermatol 1984;120:44-47
6. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris J Am Acad Dermatol 1987;16:527-533.
7. Parischa JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol. 1988;119:73-77.
8. Surrinder K, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990;29:371-374
9. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. Int J Dermatol. 1990;29 363-367.
10. Costello MJ, Jaimovitch L, Dannenberg M. Treatment of pemphigus with corticosteroid JAMA 1957,165:1249-1255.
11. Sanders SL, Brodey M, Nelson CT Pemphigus: corticosteroid treatment of pemphigus: experience with 50 cases over a period of 10 years Arch Dermatol. 1960;82:717-724.
12. Rosenberg FR, Sanders S, Nelson CT. Pemphigus. a 20-year survey of experience with 70 cases. Arch Dermatol 1976,112.962-970
13. Krain LS. Pemphigus-epidemiologic and survival characteristics of 59 patients (1959-1973). Arch Dermatol. 1974;110.862-865.
14. O'Hara K. Treatment and prognosis of pemphigus Rinsho Dermatol. 1966;8 919-931.
15. Hirone T Pemphigus: a survey of 85 patients between 1970 and 1974. J Dermatol. 1978,5.43-47
16. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Arch Dermatol. 1977;120:44-47
17. Bystryn J-C. Therapy of pemphigus. Semin Dermatol. 1988,7:186-194.
18. Lever WF, Schaumburg-Lever G Immunosuppressants and prednisone in pemphigus vulgaris. Arch Dermatol 1977;113:1236-1241.
19. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol. 1972;106 657-661.
20. Parischa JS, Wood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol. 1975;93:573-576.
21. Block LJ, Caldarelli DD, Holinger PH, et al Pemphigus of the air and food passages. Ann Otol Rhinol Laryngol. 1977;86;584-587.
22. Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris Arch Dermatol. 1978; 114:889-894.
23. Piamphongsant T. Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol 1979;6:359-363.
24. Roenigk HH, Deodhar S. Pemphigus treatment with azathioprine. Arch Dermatol. 1973;107:353-357.
25. Van Dijk TJA, Van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica. 1973,147:179-185
26. Burton JH, Greaves MW. Azathíoprine for pemphigus and pemphigoid: a four-year follow-up Br J Dermatol 1974;91:103-109.
27. Wolff K Immunosuppressive therapie bullose. Derm Hautarzt Suppl. 1976,1: 25-27
28. O'Loughlin S, Goldman GC, Provost TT. Fate of pemphigus antibody following successful therapy: preliminary evaluation of pemphigus antibody determinations to regulate therapy. Arch Dermatol. 1978;114 1969-1972.
29. Barthelemy H, Frappaz A, Camazard F, et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine J Am Acad Dermatol. 1988;18:1262-1266.
30. Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol. 1994;30:752-757
31. Singer KH, Hashimoto K, Jensen PJ, et al. Pathogenesis of autoimmunity in pemphigus. Ann Rev Immunol. 1985;3:87.
32. Wouters EA, De Clerck LS, Francx L, et al. D-Penicillamine-induced pemphigus treated with methylprednisone pulse Therapy. 1990;45:15-19
33. Fine J-D, Appell ML, Green LK, Sams WM Jr. Pemphigus vulgaris-combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988;124:236-239.
34. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment: experience of the optic neuritis treatment trial JAMA. 1993,269: 2110-2112.
35. Ahmed AR, Hombal S Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987;17:437-442.
36. McDonald CJ. Immunosuppressive agents for use in dermatology J Am Acad Dermatol. 1985;12:753-775.
37. Ahmed AR, Hombol SM. Cyclophosphamide. J Am Acad Dermatol. 1984,11: 1115-1126
38. Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980;93:109-114.
39. Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet. 1972;1:568-569.
40. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood. 1981; 58:849-851.
41. Groisser DS, Griffiths CE, Ellis CN, Voorhees JJ. A review and update of the clinical uses of cyclosporine in dermatology. Dermatol Clin. 1991;9:805-817.
42. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1:334-335.
43. Balda BR, Rosenzweig D Cyclosporin A in der behandlung von pemphigus foliaceus and pemphigus erythematosus. Hautarzt. 1986;37:454-457.
44. Alijotas J, Pedragosa R, Bosch J, Vilardell M. Prolonged remission after cyclosporin therapy in pemphigus vulgaris: report of two young siblings J Am Acad Dermatol. 1990;23:701-703.
45. Campolmi P, Bonan P, Lotti T, et al. The role of cyclosporine A in the treatment of pemphigus erythematosus. Pharmacol Ther 1991;30:890-892.
46. Bondesson L, Hammar H. Treatment of pemphigus vulgaris with ciclosporin. Dermatologica. 1990;181:308-310.
47. Tappeiner G, Groh V Treatment of pemphigus with cyclosporin. In Schindler R, ed: Ciclosporin in Autoimmune Diseases. Berlin, Germany Springer-Verlag; 1985;5:205-208.
48. Ponticelli C, Edefonti A, Ghio L, et al Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial Nephrol Dial Transplant. 1993;8:1326-1332.
49. Azana JM, de Misa RF, Boixeda JP, Ledo A. Topical cyclosporine for cicatricial pemphigoid. J Am Acad Dermatol. 1993,28:134-135.
50. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991;81:975-984
51. Austin HA, Klippel JH, Balow JE et al Therapy of lupus nephritis controlled trial of prednisone and immunosuppressive drugs. N Engl J Med. 1986,314: 614-619.
52. Boumpas DT, Austin HA III Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-745.
53. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant. 1991;6 531-535.
54. Parischa JS, Das SS. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol. 1992;31:875-877
55. Appelhans M, Bonsmann G, Orge C, Brocker EB. Dexamethasone-cyclophosphamide pulse therapy in bullous autoimmune dermatoses. Hautarzt. 1993; 44:143-147.
56. Pandya Amit G, Sontheimer R. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol. 1992;128:1626-1630
57. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent puise cyclophosphamide therapy Ann Intern Med. 1993, 119:366-369.
58. Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients. Cancer. 1988;61:451-457.
59. Green D, Rademaker AW, Briet E. A prospective randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost. 1993;70:753-757.
60. Alexopoulos E, Sakellariou G, Memmos D, Karamitsos K, Leontsini M, Papadimitriou M. Cyclophosphamide provides no additional benefit to steroid therapy in the treatment of idiopathic membranous nephropathy. Am J Kidney Dis. 1993,21.497-503.
61. Penneys NS, Eaglstein WH, Frost P. Management of pemphigus with gold compounds Arch Dermatol. 1976;112 185-187
62. Salomon D, Saurat J-H. Oral gold therapy (auranofin) in pemphigus vulgaris. Dermatologica. 1986;172:310-314.
63. Hardin JG. Rheumatoid arthritis therapy: the slow-acting agents. Hosp Pract. 1989;24:163-178.
64. Rotstein H. Gold therapy for pemphigus vulgaris. Australas J Dermatol 1977, 18:119-122.
65. Poulin Y, Perry HO, Muller SA. Pemphigus vulgaris results of treatment with gold as a steroid-sparing agent in a series of 13 patients. J Am Acad Dermatol. 1984,11:851-857.
66. Thomas I. Gold therapy and its indications in dermatology J Am Acad Dermatol. 1987;16:845-854.
67. Zvaifler NJ Gold and antimalarial therapy In McCarty DJ, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology. 9th ed. Philadelphia, Pa: Lea & Febiger; 1979:355-364.
68. Basset N, Guillot B, Michel B, Meynadier J, Guilhou J-J. Dapsone as initial treatment in superficial pemphigus. Arch Dermatol 1987;123:783-785
69. Jablonska S, Chorzelski T When and how to use sulfones in bullous diseases Int J Dermatol. 1981;20:103-105
70. Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol. 1976; 94:681-686.
71. Knight AG, Black MM, Delaney TJ. Eosinophilic spongiosis: a clinical histological and immunofluorescence correlation Clin Exp Dermatol. 1976;1 141-153.
72. Leibowitz MR, Voss SP. Juvenile pemphigus foliaceous: response to dapsone. Arch Dermatol. 1993;129:910
73. Stern RS. Systemic dapsone. Arch Dermatol. 1993;129:301-303.
74. Schiff M. Jamarsan therapy of pemphigus erythematosus observations on two patients treated with Brazilian regimen Arch Dermatol. 1961;84:153-158
75. Perry HO, Brunsting LA. Pemphigus foliaceus: further observations. Arch Dermatol. 1965;91:10-23.
76. Hymes SR, Jordon RE. Pemphigus foliaceus. Arch Dermatol. 1992;128:1462-1464.
77. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline. a review of 13 cases J Am Acad Dermatol. 1993,28.998-1000.
78. Bystryn J-C, Schenkein I, Uhr JW A model for the regulation of antibody synthesis by serum antibody. Prog Immunol. 1971;1:627-636.
79. Auerbach R, Bystryn J-C. Plasmapheresis and immunosuppressive therapy. Arch Dermatol. 1979;115:728-730.
80. Roujeau J-C, Andre C, Joneau-Fabre M, et al. Plasma exchange in pemphigus uncontrolled study of 10 patients. Arch Dermatol. 1983;119 215-221.
81. Ruocco V, Astarita C, Pisani M Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica 1984,168:219-223.
82. Bystryn J-C. Plasmapheresis therapy of pemphigus Arch Dermatol 1988;124: 1702-1704.
83. Euler HH, Loffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Dermatol 1987, 123 1205-1210
84. Jarrousse B, Blanchi P, Lhote F, et al Synchronisation d'echanges plasmatiques et de cyclophosphamide dans les maladies systemiques severes étude consecutive de 10 malades Presse Med. 1993;22:293-298.
85. Terman DS, Garcia-Rinaldi R, Danneman B, et al Specific suppression of antibody rebound after extracorporeal immunoadsorption: comparison of single versus combination chemotherapeutic agents. Clin Exp Immunol. 1978,34:32-41.
86. Reimann PM, Mason PD. Plasmapheresis: technique and complications. Intensive Care Med. 1990;16:3-10.
87. Rook AH, Heald PW, Nahass GT, et al. Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris: preliminary report. Yale J Biol Med. 1989;62.647-652.
88. Gollnick HPM, Owsianowski M, Taube KM, Orfanos CE Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photophoresis. J Am Acad Dermatol. 1993,28:122-124.
89. Liang G, Nahass G, Kerdel FA Pemphigus vulgaris treated with photophoresis J Am Acad Dermatol. 1992;26:779-780.